Following Antoine Griezmann, another French football superstar has officially taken a stake in Alan. Kylian Mbappé, the guest of honor at the company’s keynote event held this Monday in Paris, announced that he is investing in the firm that is reshaping the health insurance market.

To acquire his stake, the Real Madrid forward relied on his investment fund, Coalition Capital. The investment is part of a €100 million funding round announced by Alan just a few days ago, bringing the company’s valuation to €5 billion. While the exact size of Mbappé’s stake has not been disclosed, it is said to be “significant,” according to Jean-Charles Samuelian, co-founder and CEO of Alan.

Already an Investor in Sorare

Mbappé’s investment is coupled with a partnership aimed at boosting Alan’s visibility both in France and internationally, as well as co-developing services within the company’s app for its 1.1 million users.

“Just like in sports, I want to build for the long term by investing in projects that align with my values. When it comes to prevention and health, it’s essential in my profession,” said the Bondy-born player on stage.

Among the first initiatives, Alan users will soon be able to “challenge” Kylian Mbappé in the mobile app starting in April by tracking their steps against his. Those who outperform him will be entered into a draw to meet him in person. Interactive quizzes will also reveal the former PSG player’s health routines, which will be used by Alan’s AI-powered health assistant, Mo, to deliver personalized recommendations tailored to each user’s lifestyle.

“The goal is for everyone—especially those in this room—to become champions of their own lives,” he added.

Additional features focused on prevention, concentration, stress management, nutrition, sleep, and physical activity are expected to follow.

This is not Mbappé’s first move into the French Tech ecosystem. In 2022, he invested in Sorare, where he also serves as an ambassador.

Acquisition of Aro to Accelerate Preventive Health

Beyond Mbappé’s presence, Alan used the event to provide updates on its growth and unveil new initiatives. Notably, the company announced the acquisition of Aro, a startup specializing in preventive health.

Gaspard Hauet, Aro’s co-founder, took the stage to introduce Alan Precision—a new service offering comprehensive blood tests twice a year. The service analyzes more than 80 biomarkers to detect early signs of deficiencies and chronic conditions, and then generates personalized action plans to improve users’ overall health.

“It’s a compass to help people reach their full health potential,” said Hauet.

Alan Precision will launch this summer at a price of €249, with a waiting list already open. This new offering positions Alan alongside other preventive health startups such as Zoï, Kor, and Lucis.

For comparison, a full check-up with Zoï—founded by Ismaël Emelien, a key architect of Emmanuel Macron’s 2017 presidential campaign—costs between €980 and €3,600 and includes advanced clinical and imaging tests in dedicated centers. Meanwhile, Lucis offers blood, urine, and saliva testing packages priced between €190 and €490.

Profitability in France

Ten years after its founding, Alan generated €785 million in annual recurring revenue (ARR) last year, up from €505 million in 2024, and is targeting €1 billion this year. The company says it has reached profitability in France and aims to achieve profitability at the group level by 2027.

Now operating in four countries—France, Belgium, Spain, and Canada—Alan employs around 800 people, many of whom were present at the Musée du Quai Branly to celebrate the company’s first decade.

Jean-Charles Samuelian has already set a date for the next milestone: ten years from now—echoing the famous song by Patrick Bruel.